Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...
Teva reported growth for the second year in a row. Despite exceeding Wall Street targets, the company's guidance came up short. Teva reported earnings before trading began on Wednesday. The ...
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full-year 2024 financial results. In the ...
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.5% and 0.9% ...
Slip on a pair of super shoes and you will immediately want to run—they demand that your feet bounce and take off. On the other hand, slip on a pair of walking shoes and you might notice how ...
Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...
Here’s how it works. We all know how important it is to wear a good pair of running shoes to avoid injury, feel comfortable, and perform at our best. But with so many options out there ...
In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...
Israeli generics giant Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2024. 2024 revenues of $16.5 billion reflect an ...